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Simultaneous CK2/TNIK/DYRK1 inhibition by
108600 suppresses triple negative breast cancer
stem cells and chemotherapy-resistant disease
3,

1234567890():,;

Katsutoshi Sato 1,6, Amol A. Padgaonkar2,6, Stacey J. Baker2, Stephen C. Cosenza2, Olga Rechkoblit
D. R. C. Venkata Subbaiah2, Josep Domingo-Domenech4, Alison Bartkowski 1, Elisa R. Port5,
Aneel K. Aggarwal 3, M. V. Ramana Reddy2, Hanna Y. Irie 1,2,7 ✉ & E. Premkumar Reddy2,7 ✉

Triple negative breast cancer (TNBC) remains challenging because of heterogeneous
responses to chemotherapy. Incomplete response is associated with a greater risk of
metastatic progression. Therefore, treatments that target chemotherapy-resistant TNBC and
enhance chemosensitivity would improve outcomes for these high-risk patients. Breast
cancer stem cell-like cells (BCSCs) have been proposed to represent a chemotherapyresistant subpopulation responsible for tumor initiation, progression and metastases. Targeting this population could lead to improved TNBC disease control. Here, we describe a
novel multi-kinase inhibitor, 108600, that targets the TNBC BCSC population. 108600
treatment suppresses growth, colony and mammosphere forming capacity of BCSCs and
induces G2M arrest and apoptosis of TNBC cells. In vivo, 108600 treatment of mice bearing
triple negative tumors results in the induction of apoptosis and overcomes chemotherapy
resistance. Finally, treatment with 108600 and chemotherapy suppresses growth of preestablished TNBC metastases, providing additional support for the clinical translation of this
agent to clinical trials.
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riple negative breast cancers (TNBCs), deﬁned as tumors
that lack expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor
receptor-2 (HER2) represent ~15% of diagnosed breast cancers1.
While some patients do well with standard of care multi-modality
therapy that includes chemotherapy, many patients have suboptimal responses. Chemotherapy resistance is a negative prognostic factor with poorer survival in TNBC2,3 and is thought to be
due to the presence of breast cancer stem cells (BCSCs), a subpopulation of cells that resides within the tumor4,5. These cells are
relatively resistant to standard chemotherapeutic agents, and have
the ability to renew, grow as mammospheres in vitro and initiate
tumor development in mouse models. At a molecular level,
BCSCs are generally deﬁned as CD44highCD24lowEpCAM+ and/
or have high levels of aldehyde dehydrogenase-1 (ALDH1high)
enzyme activity6,7. Several studies have shown that sorted human
breast cancer CD44high/CD24lowEpCAM+ cells have increased
tumorigenic potential in mouse xenograft assays6. Like normal
stem cells, BCSCs divide asymmetrically, generating additional
BCSCs that display the same characteristics as the parental cell
(CD44high/CD24low) as well as differentiate into daughter cells
(CD44lowCD24low).
The metastatic and invasive properties of TNBC are attributed
to CD44, which is thought to mediate invasion via urokinase-type
plasminogen activators (uPAs)8,9. Furthermore, ALDH1, a BCSC
marker, is statistically correlated with decreased survival and poor
prognosis10,11. Together, these studies strongly suggest that targeting CD44high/CD24low/ALDH1+ cells is likely to result in a
successful therapeutic strategy. Identiﬁcation of new proteins and
pathways in tumor cells from RNAi screens has presented new
opportunities for drug development, both in terms of using RNAi
as a therapeutic agent and identifying new targets. However, a
common ﬁnding from these screens is that many genes are
required for the survival of tumor cells, making it difﬁcult to
select a single target for drug development12,13. This complexity
has led to a recent and renewed interest in targeted, polypharmacological approaches for developing multi-kinase inhibitors with low toxicity proﬁles14.
In an attempt to understand the molecular basis of TNBC
growth and to develop a targeted therapy for this disease, we
designed an approach where we combined the identiﬁcation of
“oncogenic kinases” with drug discovery. Because growth of most
tumors is dictated by the activation of kinase cascades, we
designed a strategy to identify possible oncogenic kinases upon
which a breast cancer stem cell might be dependent. This was
made possible because of our library of ~4000 novel compounds,
which consists of ~2000 ATP-mimetics which function as kinase
inhibitors. We used this group of compounds to determine if any
of these agents can induce the death of CD44high/CD24low BCSCs
puriﬁed from TNBC cells. This approach allowed two important
aspects of drug discovery to occur simultaneously: the identiﬁcation of new therapeutic targets and the development of novel
pharmaceuticals that can inhibit these targets. This strategy
identiﬁed 108600, which shows remarkable efﬁcacy against triple
negative breast tumor cells, including the BCSC population, with
minimal toxicity towards normal cells. Our studies presented here
show that 108600 is a potent inhibitor of TNBC growth in vitro
and in vivo, including chemotherapy-resistant and metastatic
disease. Our data support clinical translation of 108600 as a
complement to standard chemotherapy for high risk, aggressive
TNBC to improve patient outcomes.
Results
Derivation of a small molecule inhibitor of TNBC growth. In
this study, we used phenotypic screening of TNBCs as an
2

approach to identify the nature of signal transduction pathways
activated in these cells and simultaneously identify compounds
that can target these pathways. To accomplish this goal, we used
four TNBC cell lines MDA-MB-231, MDA-MB-468, Hs578T,
and BT-20 as well as the CD44high/CD24low BCSC puriﬁed
populations derived from these lines to screen a compound
library synthesized in our laboratory to identify compounds that
induce apoptosis of these cells. This strategy identiﬁed 108600
(Fig. 1A), which showed remarkable toxicity towards the bulk and
BCSC populations of these cell lines, with little toxicity to normal
cells. This compound was assayed against a panel of 285 functional kinases by Reaction Biology Corporation (RBC), which
revealed that 108600 is a multi-kinase inhibitor and inhibits
CK2α1, α2, DYRK1A, 1B, and DYRK2 and TNIK at low nanomolar concentrations (Fig. 1B and Supplementary Fig 1).
To conﬁrm that 108600 inhibited endogenous CK2, DYRK,
and TNIK activity in a dose-dependent manner in TNBC cells, we
evaluated the effect of 108600 treatment on established substrates
of these kinases in MDA-MB231 and Hs578T cells, as well as
organoids derived from a primary TNBC with intrinsic resistance
to anthracycline and taxane-based chemotherapy (CTG1883).
CK2 has been shown to phosphorylate AKT1 at serine (S) 129,
which promotes a hyperactivated state of AKT115,16. Additionally, threonine (Thr) 286 of CYCLIN D1 and serine (Ser)10 of
p27 are known phosphorylation sites for DYRK1A17. Treatment
with 108600 led to decreased phosphorylation at these sites
(Fig. 1C and supplementary Fig 2), as well as decreased levels of
autophosphorylated DYRK1A/B (Supplementary Fig 3), indicating that 108600 treatment suppresses endogenous CK2α and
DYRK1 activities in TNBC cells. We also examined the effect of
108600 on the activity of TNIK, which regulates Wnt signaling as
a core component of the β-catenin transcriptional complex.
AXIN2 expression, which is induced by activated Wnt/TCF/
LEF18–20 was used as readout of TNIK activity, and as predicted,
was suppressed in 108600-treated cells (Fig. 1C).
108600 inhibits viability of TNBC CD44high/CD24low breast
cancer stem cells. We next evaluated the effect of 108600 treatment on growth of an expanded panel of breast cancer cell lines,
as well as six normal and nontransformed cells. The kinases
targeted by 108600 are robustly expressed in most TNBC cell
lines, with relatively lower expression in normal cells (ﬁbroblasts,
immortalized human-mesenchymal stem cells) (Supplementary
Fig. 4). 108600 potently inhibited the viability of all triple negative
and other breast tumor cell lines with little or no toxicity against
normal cells, including normal mammary epithelial cell lines
derived from two different donors (Fig. 1D). The growth suppression of TNBC cells (MDA-MB231 and Hs578T) observed
with 108600 treatment was phenocopied by simultaneous transfection of cells with three siRNA pools targeting CK2α, DYRK1A,
and TNIK (Fig. 1E). Transfection of MDA-MB-231 or
Hs578T cells with siRNA pools individually targeting CK2α,
DYRK1A, or TNIK had little or moderate effects on growth,
supporting the need for simultaneous multi-kinase targeting
(Supplementary Fig. 5). Individual siRNAs targeting CK2α,
DYRK1A, or TNIK suppressed phosphorylation of their respective, reported substrates, thereby phenocopying the effects of
108600 treatment and further validating that these kinases are
indeed targeted by 108600 (Supplementary Fig 6).
To speciﬁcally examine the effect of 108600 treatment on the
BCSC population, we puriﬁed CD44high/CD24low cells from two
TNBC cell lines (MDA-MB-231 and Hs578T) by FACS
(according to schema in Supplementary Fig 7) and examined
the effects of 108600 treatment on colony and mammosphere
forming capabilities of the CD44high/CD24low fraction. 108600
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Fig. 1 108600 suppresses the growth of TNBC stem cells. A Chemical structure of 108600. B IC50 values for inhibition of 108600 target kinases.
C 108600 inhibits phosphorylation of CK2α, DYRK1A and TNIK substrates. Lysates derived from MDA-MB-231 and Hs578T cells treated for 24 h with
108600 at the indicated concentrations were probed for expression of phospho-AKT1 (Ser129), phospho-CYCLIN D1 (Thr286), and AXIN2. The blots are
representative of three independent experiments. Samples derive from the same experiment and the blots processed in parallel. D GI50 values for growth
inhibition of breast cancer and normal cells treated with 108600. E Simultaneous siRNA-mediated knockdown of CK2α, DYRK1A, and TNIK suppresses
proliferation of MDA-MB-231 and Hs578T cells. siRNA-transfected cells were counted on the indicated days. All data represent mean values ± standard
deviation obtained from three independent biological replicates. The statistical difference between the target and nontarget siRNA treated groups was
tested using two-way ANOVA (two-sided). Knockdown was conﬁrmed by western blot analysis, which was performed three times. Samples derive from
the same experiment and the blots processed in parallel. F 108600 treatment suppresses colony and G mammosphere formation of CD44high/CD24low
stem cell fraction of MDA-MB-231 and Hs578T cells. For colony assays, CD44high/CD24low cells were puriﬁed by FACS, treated with the indicated
concentrations of 108600 for 72 h, washed and allowed to grow for 7–14 days in drug-free medium. Cells were ﬁxed with 4% paraformaldehyde in PBS,
stained with crystal violet solution and colonies quantiﬁed microscopically. All data points represent mean value ± standard deviation. Scale bars = 50 µm.
Values in F and G represent the mean percentage of colony and sphere formation ±SD, respectively, relative to that of DMSO, which was set to 100%, in
three independent experiments. Source data are provided as a source data ﬁle.

potently inhibited colony growth of the CD44high/CD24low
population, as well as CD44low/CD24low cells (Fig. 1F). We also
examined the effects of 108600 on patient-derived TNBC cells in
2D and 3D cultures using commercially available CD44high/
CD24low/ALDH+ breast cancer stem cells derived from a TNBC
patient. 108600 potently inhibited mammosphere formation by
these cells in in vitro 2D and 3D cultures (Supplementary Fig. 8),
which is in agreement with the data obtained from sorted
populations isolated from established TNBC cell lines (Fig. 1G).
Structure of CK2α1 in complex with 108600. To gain an
understanding of the mechanisms by which 108600 inhibits CK2
kinases, we expressed, puriﬁed, crystallized, and determined the
structure of the human CK2α1 catalytic domain in complex with
108600 (Supplementary Fig. 11). The structure was solved by
molecular replacement and reﬁned to 1.80 Å resolution. The
structure of CK2α1 has the familiar bilobal architecture of a
protein kinase, composed of N-terminal lobe followed by a larger
C-terminal lobe (Fig. 2B). 108600 binds in the cleft between the
two domains, where ATP would normally be accommodated
(Figs. 2A, B and Supplementary Fig. 12) and adopts a conformation where the NO2 group and the aromatic ring are
coplanar (Fig. 2C). The density for 2,6-dichlorobenzyl ring of the
drug is disordered due to the conformational ﬂexibility of this

aromatic moiety in the solvent-exposed region of the active site
(Fig. 2A–D).
Previous work has shown that CK2 is able to use both ATP and
GTP as phosphoryl donors with similar efﬁciencies. The crystal
structure of the human CK2α1 in complex with the ATP
nonhydrolysable analogue AMP-PNP has been determined at a
1.3 Å resolution (Fig. 2E)21. The CK2α1 (Zea mays) complex
structure with GMP-PNP resolved at 2.2 Å showed that GMPPNP and water molecules mimic AMP-PNP in the active site of
protein kinase CK222. Our studies show that the O3 and N4 of
108600 take the positions of the O6 and N1 atoms of GMP-PNP,
respectively, and maintain the same interactions with the
backbone atoms of His115 and Val116 (Fig. 2D, F). Moreover,
the NO2 group of the drug is near the position that is occupied by
the Pα group of AMP-PNP or GMP-PNP and establishes a
hydrogen bond with the side chain of Lys68 (Fig. 2D, E, F). In
addition, the central benzothiazinone and aromatic rings are
involved in numerous hydrophobic contacts with residues such as
Leu45, Val66, Ile95, Phe113, and Ile174 that line the ATP/GTP
binding cavity (Supplementary Fig. 12). The carbonyl group of
the thiazone ring interacts with the main chain NH group of
His115 and the NH proton of the ring establishes a hydrogen
bond with the main chain carbonyl group of Val116. Importantly,
a water molecule (wat1) in the drug complex forms hydrogen

NATURE COMMUNICATIONS | (2021)12:4671 | https://doi.org/10.1038/s41467-021-24878-z | www.nature.com/naturecommunications

3

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24878-z

O

A

B

HN4 3 2
1S
6

S

O
O
Cl

Cl

E

Glu114
His115

N

Glu114
His115
Val116

Val116

OH

5

O

D

wat3

wat5

wat2 wat1

wat1

O

wat4

108600

Lys68 Glu81

108600

Lys68 Glu81

AMP-PN
Mg 2+

Mg 2+

C
Glu114
wat1

F

Glu81

His115
Lys68
Val116

so

lve

e
nt

xp

os

e

d
de

ge

wat3
wat6

108600
AMP-PN
GMP-PNP

Lys68 Glu81

I

β

Ser106

α

α

Mg 2+

J

β

wat1

wat4

wat7

Mg 2+

wat2

wat7

wat3

GMP-PNP

H

G

Glu114
His115
Val116

Arg107
Ser106

Val105
Asp103
Val105
Pro104
Tyr188

β

Gly189
Pro104
Arg107
Asp103

Phe190

CK2 holoenzyme

−CK2α1 with AMP-PNP in holoenzyme
(”open” β4−β5-loop)

−CK2α1 with 108600
(”closed” β4−β5-loop)

Fig. 2 Crystal structure of 108600 in complex with CK2α. A Chemical structure of 108600. B Overall structure of the CK2α1-108600 complex. CK2α1
protein (pink) is shown in cartoon. 108600 is shown in sticks. A simulated annealing Fo-Fc omit electron density map for 108600 (green) is contoured at
3.0 σ-level at 1.80 Å resolution. C Zoom-in view of 108600 interactions with CK2α1. The water molecule (wat1) is shown as a red sphere. The electron
density for the 2,6-dichlorobenzyl ring of the drug is disordered due to the conformational ﬂexibility of this aromatic moiety in the solvent-exposed region
of the active site; D A close-up view of 108600 interactions with CK2α1 depicting a surface view of the drug. E, F AMP-PNP (PDB ID: 3NSZ)21 (the γphosphate of AMP-PNP is hydrolyzed due to the acidic crystallization conditions to yield AMP-PN) and GMP-PNP (PDB ID: 1DAY)22 accommodations
within the active site of CK2α1. The water-mediated ligand–protein interactions are also shown. G 108600, AMP-PN, and GMP-PNP in surface
representation in the active site of CK2α1. Signiﬁcantly, the drug mimics not only the shape and electrostatics of AMP-PN and GMP-PNP, but also their
hydration patterns. H–J 108600 induces change in the conformation of the β4-β5 loop, which interacts with the regulatory CK2β subunit in the holoenzyme
complex. H Superposition of CK2α1 structures with AMP-PNP alone (PDB ID: 3NSZ, beige) and integrated in the holoenzyme complex with CK2β
regulatory subunit dimer (PDB ID: 1JWH, cyan)23, CK2α1 in the absence of ligand (PDB ID: 1NAZ, blue), and CK2α1 with 108600 (pink). Black frame
highlights the β4-β5 loop. I CK2 kinase holoenzyme (PDB ID: 1JWH) and CK2α1-108600 complex. The holoenzyme consists of the two CK2α1 subunits
(cyan) and the two CK2β regulatory subunits (green). CK2α1 subunit of the holoenzyme contains AMP-PNP. The CK2α1 β4-β5 loop region and its
interaction with the loop of the CK2β subunit are highlighted by a thick black frame. J The “closed” conformation of the β4–β5 loop in the CK2α1/108600
complex (pink) appears to interfere with interactions with the loop of the CK2β subunit (green–blue) in the CK2 holoenzyme2.

bonds with the OH group of the drug and the side chain of Glu81
(Fig. 2D). Wat1 is also observed in the complex with AMP-PNP
(Fig. 2E). Moreover, the drug covers the area where wat2, wat3,
and wat4 are bound in the AMP-PNP/CK2α1 complex (Fig. 2E)
and wat7 in the GMP-PNP/ CK2α1 complex (Fig. 2F). To
compare the binding modes of 108600 and AMP-PNP/GMPPNP, the coordinates for all complexes were superimposed
(Fig. 2G). Signiﬁcantly, the drug mimics not only the shape and
electrostatics of AMP-PNP/GMP-PNP, but also their hydration
patterns in the CK2α1 active site pocket (Fig. 2D, E, F, G).
108600 induces a conformational change in CK2α1, which is
not conducive to holoenzyme formation. The CK2 holoenzyme
consists of two catalytic subunits (CK2α1 or CK2α2), which
interact with a CK2β dimer forming a transient complex23.
4

Interestingly, the CK2 holoenzyme has been shown to bind
substrates and activate them in a kinase-independent manner24.
CK2α1-AMP-PNP either alone or integrated into the holoenzyme
has the loop connecting β4 and β5 sheets in the “open” conformation (Fig. 2H) conductive to integration with CK2β subunit
(Fig. 2I, J). In the absence of AMP-PNP, the β4–β5 loop is in the
“closed” conformation (Fig. 2H). Intriguingly, in the presence of
108600, the β4–β5 loop adopts the “closed” conformation that is
obstructive to holoenzyme formation (Fig. 2H, I, J). Hence,
108600 binding to CK2α1 appears to induce a conformational
change, which represents a state that is not conducive to
holoenzyme formation (Fig. 2I, J). 108600 may thus inhibit CK2
as a both a competitive inhibitor of ATP/GTP and as an allosteric
inhibitor that weakens the interaction between C2Kα and C2Kβ
in vivo.
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Fig. 3 108600 suppresses tubulin polymerization. A Recombinant CK2α or CK2β or CK2α + CK2β holoenzyme preparations were pretreated with either
DMSO or 108600 for 5 min and the mixture was added to MAP-free tubulins in buffer containing 1 mM GTP. The reaction mixtures were transferred to a
heated spectrophotometer and tubulin polymerization was evaluated by monitoring absorbance at 340 nm over a period of 40 min. Representative results
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growing HeLa cells were treated with vehicle (DMSO) or 108600 for 12 h, ﬁxed and stained with α-tubulin and pericentrin antibodies and DAPI.
Representative images of two technical replicates using confocal microscopy show abnormal mitotic spindle formation induced by treatment with 108600.
Scale bars = 10 µm and 100 µm for control and 108600-treated cells, respectively. Source data are provided as a source data ﬁle.

108600 inhibits tubulin polymerization and causes abnormal
mitosis. Small interfering RNAs directed against CK2 α and β
subunits exhibit mitotic abnormalities ranging from defects in
centrosome duplication, anaphase spindle elongation, and chromosome mis-segregation25. The CK2 holoenzyme is an established microtubule associated protein (MAP) that aids in tubulin
polymerization and regulates microtubule cytoskeletal
reorganization26,27. Since 108600 induces a conformational
change in the CK2α subunit by potentially interfering with its
ability to bind to the β-subunit, we examined the effects 108600
on CK2-holoenzyme-mediated tubulin dynamics in vitro and
assessed its effects on mitosis. We adapted and employed a
published protocol27, which measures CK2-holoenzymemediated de novo tubulin polymerization. MAP-free tubulin
preparations were incubated with recombinant puriﬁed CK2α,
CK2β-His-Sumo or pre-assembled (CK2α-CK2β) holoenzyme,
respectively, and the extent of tubulin polymerization was measured over time. We did not observe any tubulin polymerization
in the presence of individual CK2 subunits (CK2α or CK2β), even
after a prolonged incubation (Fig. 3A, B). However, addition of
the CK2 holoenzyme to tubulin resulted in enhanced polymerization, which is in agreement with published observations
that the CK2 holoenzyme promotes tubulin polymerization.
When we pretreated the CK2 holoenzyme with 108600, we
observed a decrease in CK2-holoenzyme-mediated tubulin polymerization (Fig. 3A, B). These effects suggest that 108600 inhibits
CK2-holoenzyme formation and hence, tubulin dynamics.
To study the mitotic phenotype induced by 108600, cells were
grown on collagen coated glass coverslips and treated with either
DMSO or 108600 overnight and stained for α-tubulin and the
centrosomal marker, pericentrin. While DMSO-treated mitotic
cells displayed normal bipolar spindle architecture, the cells
treated with 108600 formed multipolar spindles and multiple
centrosomes (Fig. 3C). These effects are similar to those observed
with CK2 subunit inhibition reported by Bettencourt-Dias et al25,
further supporting the fact that 108600 inhibits CK2-dependent
functions.
108600 treatment induces cell cycle arrest and apoptosis of
TNBC cells. Given the potent inhibition of TNBC cell growth
observed with 108600 treatment (Fig. 1) and its effects on tubulin
polymerization and mitosis (Fig. 3), we assessed cell cycle progression of triple negative MDA-MB-231 cells and CTG1883
TNBC organoids treated with increasing concentrations of

108600 for varying periods of time. Treatment with 108600
resulted in a potent, dose- and time-dependent G2/M arrest
(Fig. 4A, B and Supplementary Fig. 13) as assessed by ﬂow
cytometric analysis (Supplementary Fig 10). The percentages of
cells in the G2/M phase were clearly increased with 108600
treatment, while the fraction of cells in the G1 or S phases concomitantly decreased. Notably, 108600 treatment increased the
percentage of cells in the sub-G1 fraction, indicating apoptotic
cells, and increased the percentage of polyploid or aneuploid cells.
Interestingly, when we performed these studies with normal
proliferating cells such as hMSC-hTERT (immortalized humanmesenchymal stem) or MCF-10A (human mammary epithelial)
cells, which express very low levels of CK2, we observed minimal
or no mitotic arrest in cells treated with 1 µM 108600 (Supplementary Fig 13). The majority of these cells remained in the G1
phase, with a modest increase in the G2/M population. Taken
together, these results suggest that 108600 does not induce
mitotic arrest of normal cells, which might explain its selective
toxicity against tumor cells.
These observations strongly suggest that treatment of TNBC
with 108600 leads to prolonged G2/M arrest and eventually
induces cell death. To more speciﬁcally determine whether
108600 treatment induces apoptosis, we examined levels of
cleaved PARP and cleaved Caspase 3 in cells treated with
increasing doses of 108600 for 24–48 h. Increased PARP cleavage,
which was blocked by the addition of the ZVAD caspase
inhibitor, was detected in both MDA-MB-231 cells and TNBC
PDX organoids (Fig. 4C, D, supporting the induction of apoptosis
by 108600.
Chemotherapy-resistant TNBCs are sensitive to 108600 treatment.
Patients with TNBC are often treated with anthracycline and taxanebased chemotherapy as standard of care. However, as response to
these chemotherapies is heterogenous, we determined whether
108600 treatment would also be effective in suppressing viability and
inducing apoptosis of chemotherapy-resistant TNBC cells in vitro.
We generated paclitaxel-resistant variants of the MDA-MB-231 and
BT-20 cell lines by exposing them to increasing concentrations of
paclitaxel (PTX). Resistance was validated by cell viability, colony
formation and apoptosis assays. After continuous exposure and
passaging in PTX-containing medium, we obtained MDA-MB-231
and BT-20 cells (MDA-MB-231-TR and BT-20-TR), which exhibited
greater than 250-fold resistance to PTX as compared to the parental,
PTX-sensitive (TS) cell lines (Fig. 5B).
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Fig. 4 108600 induces G2/M arrest and apoptosis of TNBC cells and organoids. A MDA-MB-231 cells were treated with the indicated concentrations of
108600, stained with propidium iodide (PI) and analyzed by ﬂow cytometry. Statistical differences were calculated using Dunnett’s test (two-sided). A p
value of less than 0.05 is indicated by an asterisk and is regarded as statistically signiﬁcant. B CTG1883 TNBC organoids were treated with 108600 (0.5
µM), stained with PI and analyzed by ﬂow cytometry. All data represent mean values ± standard deviation obtained from three independent biological
replicates. Statistical differences were tested using t-test (two-sided). A p value of less than 0.05 is indicated by an asterisk and is regarded as statistically
signiﬁcant. C MDA-MB-231 cells were treated with 108600 for 24 or 48 h. Lysates derived from these cells were subjected to western blot analysis and
probed for the expression of total or cleaved PARP (top), which is inhibited by a 2 h pretreatment with the ZVAD (50 µM) caspase inhibitor (bottom).
Samples derive from the same experiment and the blots processed in parallel. The blots are representative of three independent experiments. D CTG1883
organoids were treated with 108600 for 48 h. Lysates from these cells were probed for the expression of total or cleaved PARP and caspase 3. All westerns
were performed on the same gel. The blot is representative of three independent experiments. Source data are provided as a source data ﬁle.

We investigated whether the CD44highCD24-/low stem-cell-like
population was increased in the PTX-resistant cell lines, similar to
those of patients who are refractory to taxane therapy28.
Interestingly, western blot analysis of parental and MDA-MB231-TR cells showed an increase in the level of CD44 expression
relative to the parental cell line, which might reﬂect an increase in
the BCSC population (Fig. 5C). In addition, target kinases of
108600, such as DYRK1A, were also upregulated in the PTX-R
variant (Fig. 5C). To determine whether 108600 inhibits signaling
in the context of PTX-resistance, PTX-R MDA-MB-231 cells were
treated with increasing concentrations of 108600 for 24 h and the
phosphorylation status of CK2, DYRK, and TNIK substrates
analyzed by western blot analysis. Fig. 5D and Supplementary
ﬁg. 3 show that treatment with 108600 resulted in an inhibition of
both pAKT1 Ser129 and pCYCLIN D1 Thr286 phosphorylation,
as well as a reduction in the level of AXIN2 expression and
DYRK1A/B autophosphorylation, conﬁrming inhibition of these
target kinases (Fig. 5D). 108600 also potently inhibited growth
and colony formation of both PTX-sensitive and PTX-resistant
MDA-MB-231 and BT-20 cell lines with the same efﬁciency
(Fig. 5E), suggesting that it effectively overrides PTX-resistance
in vitro.
108600 inhibits the growth of TNBC in vivo. Before determining the efﬁcacy of 108600 against TNBC growth in vivo, we
6

ﬁrst established a dosing regimen based on toxicity data and
suppression of 108600 target kinase activities. We performed a
pilot study whereby CTG1883 tumor-bearing NSG mice were
treated with vehicle or 108600 (100 mg/kg) for a 5-day period.
Whole-cell extracts derived from the tumors were subjected to
western blot analysis using antibodies directed against pAKT1
Ser129, pCYCLIN D1 Thr286, and C-MYC as readouts for CK2α,
DYRK1A, and TNIK kinase inhibition, respectively. (C-MYC, like
AXIN2, is activated by Wnt/TCF/LEF signaling19,20). Fig. 6A and
supplementary ﬁg 14 show that the levels of pAKT1 Ser129,
pCYCLIN D1 Thr286 and C-MYC were decreased in the tumors
isolated from 108600-treated animals, suggesting that loss of AKT
phosphorylation and/or that of CYCLIN D1 as well as MYC
expression might serve as relevant biomarkers in vivo. Based on
the results of this experiment, administration of 108600 on a q2D
schedule at a dose of 100 mg/kg was chosen for subsequent studies in tumor-bearing mouse models.
To determine the efﬁcacy of 108600 against TNBC growth
in vivo, MDA-MB-231 cells were injected subcutaneously into the
mammary fat pads of female athymic (NCr-nu/nu) mice and
the tumors allowed to grow to a size of 100–150 mm3. The mice
were then randomly grouped and treated every other day with
50 mg/kg or 100 mg/kg of 108600 or an equal volume of placebo.
Tumor measurements and body weights were measured on the
indicated days and at the end of the study, the tumors (or site of
inoculation) harvested and subjected to further analysis. Fig. 6B
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Fig. 5 108600 suppresses the growth of chemotherapy-resistant TNBC cells. A Schematic diagram showing the strategy used for the generation of
paclitaxel-resistant TNBC cell lines. MDA-MB-231 or BT-20 cells were grown in increasing concentrations of paclitaxel and GI50 values were determined
after every passage. Each subsequent passage was maintained in the highest possible concentration of paclitaxel-containing medium. Selection was
completed when resistance reached > 200-fold; B GI50 values for paclitaxel and 108600 for parental, paclitaxel-sensitive (TS) and paclitaxel-resistant (TR)
MDA-MB-231 and BT-20 cells using CellTiter Blue in conjunction with clonogenic assays. C Expression of MDR-1, CD44, CK2, DYRK1A, EGFR, β-Catenin in
paclitaxel-sensitive and resistant MDA-MB-231 cells as determined by western blot analysis. GAPDH serves as a loading control. Images are
representative of two independent experiments. Samples derive from the same experiment and the blots processed in parallel. D Paclitaxel-resistant MDAMB-231 cells were treated with increasing concentrations of 108600 for 24 h. Lysates derived from these cells were subjected to western blot analysis
using the indicated antibodies. The blot is representative of three independent experiments. Samples derive from the same experiment and the blots
processed in parallel. E Paclitaxel-resistant MDA-MB-231 cells were treated with increasing concentrations of paclitaxel or 108600 for 72 h, washed and
allowed to grow for 7 days in drug-free growth medium. Colonies were stained with crystal violet. Source data are provided as a source data ﬁle.

shows that 108600 is a potent inhibitor of TNBC tumor growth as
judged by the reduction in tumor volumes in both 108600-treated
cohorts (Fig. 6B). The study had to be terminated at the end of
22 days due to the size of tumors in the control group, which
began to undergo necrosis. Measurement of body weights and
gross visual examination of drug-treated animals did not show
any detectable toxicity (Supplementary Fig. 15).
To expand the clinical relevance of 108600 as a therapeutic for
TNBC, we also examined the effect of 108600 on the growth of an
invasive ductal carcinoma TNBC PDX (TM00098), which, like
the parental MDA-MB-231 cell line, is sensitive to taxane
therapy. Tumor-bearing nod/scid/gamma (NSG) mice were
randomly assigned to two groups and treated with 108600 (100
mg/kg) or an equal volume of placebo as described above. The
results presented in Fig. 6C shows that treatment with
108600 suppressed the growth of this tumor in vivo without
adverse effects on the animals’ body weights (Supplementary
Fig. 15)
108600 suppresses aggressive TNBC PDX growth in combination with chemotherapy. To further evaluate the efﬁcacy of
108600 in suppressing growth of chemotherapy-resistant TNBC
in vivo, we utilized clinically annotated PDX models of drugresistant TNBC that we have been developing as part of an
ongoing co-clinical study. We prioritized models based on relative chemotherapy resistance of the original patient’s cancer from
which the PDX model was derived, as well as levels of expression
of 108600 targets (CK2, DYRK, and TNIK kinases; supplementary ﬁg 16). After establishing the dose of 108600 that is sufﬁcient
to suppress established substrates of 108600 target kinases
(Fig. 6A and supplementary ﬁg 16), we propagated two PDX

models, CTG1883 and CTG2397, for use in efﬁcacy studies based
on robust expression of 108600 targets. As previously stated,
CTG1883 is derived from a primary TNBC with intrinsic resistance to anthracycline and taxane-based chemotherapy, while
CTG2397 is derived from a metastatic TNBC that recurred
despite anthracycline and taxane-based chemotherapy. For these
studies, mice bearing PDX tumor grafts were treated with either
vehicle control, PTX (10 mg/kg q4D), 108600 (100 mg/kg q2D) or
a combination of PTX/108600, and tumor growth was monitored
over a period of 12–24 days. While paclitaxel had a moderate or
minimal inhibitory effect on tumor growth in the CTG1883 and
CTG2397 models, respectively, 108600 as a single agent signiﬁcantly suppressed tumor growth in both models. However, the
combination of 108600 and PTX resulted in a near complete
suppression of tumor growth in both chemotherapy-resistant
PDX models, as assessed by caliper measurement and endpoint
tumor weight (Fig. 6D) without adversely affecting the animals’
body weights (Supplementary Fig. 15). Combined treatment with
108600/PTX synergistically inhibited tumor growth, as supported
by an interaction effect on rates of change in tumor growth in this
treatment group when compared to those in the 108600 and PTX
treated cohorts (Supplementary Fig 17).
We next evaluated the effect of 108600 on the stem-cell-like
population in these PDX tumors by assessing ALDH activity in
organoids derived from these models (Fig. 6E and Supplementary
Fig. 18). 108600 treatment suppressed the frequency of the
ALDH-high fraction in CTG1883 organoid cultures in a dosedependent manner. These results collectively support 108600’s
efﬁcacy against chemotherapy-resistant TNBC is achieved due to
suppression of the BCSC population, thereby enhancing sensitivity to chemotherapy.
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Fig. 6 108600 suppresses growth of TNBC cell line and PDX tumor grafts. A 108600 inhibits phosphorylation of CK2α and DYRK1A substrates in vivo.
NSG mice bearing CTG1883 PDX tumor grafts were treated with 108600 (100 mg/kg) or DMSO for 5 days (n = 5). Box plots show levels of phosphoAKT1Ser129 and phospho-CYCLIN D1Thr 286 normalized to those of their respective total proteins and GAPDH. Variances were tested using F-tests (twosided). P values were calculated using a t-test (two-sided). Samples derive from the same experiment and the blots processed in parallel. B Nude mice
bearing MDA-MB-231 xenografts were treated with vehicle or 108600 (50 mg/kg or 100 mg/kg) for 21 days. Tumor volumes were measured on the
indicated days. (n = 7 for vehicle- and 108600 (100 mg/kg)-treated animals; n = 6 for 108600 (50 mg/kg)-treated animals). Statistical differences were
assessed by two-way ANOVA (two-sided). Data represent mean ± SEM. C 108600 suppresses growth of paclitaxel-sensitive PDX tumors. TM00098
tumor-bearing NSG mice were randomly assigned to groups and treated with vehicle (n = 4) or 108600 (100 mg/kg q2D) (n = 5). Error bars represent
mean ± SEM. Statistical differences were assessed by two-way ANOVA (two-sided). D Chemotherapy-resistant PDX growth suppression by 108600. PDX
models were treated with DMSO (n = 5 for CTG1883; n = 7 for CTG2397), paclitaxel (10 mg/kg, n = 6 for CTG1883; n = 5 for CTG2397), 108600 (100
mg/kg, n = 6 for CTG1883; n = 7 for CTG2397) or a combination of paclitaxel and 108600 (n = 6 for CTG1883; n = 6 for CTG2397). Paclitaxel and
108600 were administered q4d and q2d, respectively. Statistical differences were assessed by two-way ANOVA (two-sided). Weights of tumors
harvested at study endpoints are shown. Data represent mean ± SD. Statistical differences were assessed using a t-test with false discovery rate correction
calculated by the Benjamini–Hochberg method. Experiments were performed twice with each model. E 108600 decreased the ALDHhigh fraction in
CTG2397 organoids. ALDH activity was measured in organoids treated with 108600 for 48 h. DEAB-treated organoids served as negative controls. Mean
values ± SD from three independent experiments are shown. Statistical differences between the ALDHhigh fractions were tested using one-way ANOVA
(two-sided) and Dunnett’s test (two-sided). p values of less than 0.05 were considered statistically signiﬁcant. Source data are provided as a source
data ﬁle.

108600 suppresses growth of pre-established TNBC metastases.
The results from the above in vivo studies encouraged us to
investigate the efﬁcacy of 108600 treatment against TNBC that
has already metastasized. This is particularly important as most
novel therapeutics are ﬁrst evaluated in the context of advanced,
metastatic disease that has previously been exposed to prior
chemotherapy. For these studies, MDA-MB231 LM2-4/mCherry
Luc cells (LM2-4/mCherry), a luciferase and mCherry-expressing
derivative of MDA-MB-231 that readily disseminates from the
primary site to form metastases in lung and liver, was used for
modeling metastatic breast cancer29. LM2-4/mCherry Luc cells
were implanted into the mammary fat pads of NSG mice and the
primary tumors removed prior to evidence of metastasis (11 days
post-implantation). Serial in vivo imaging (IVIS) was performed
to monitor the development of metastases and once metastases
were detected in the majority of animals (primarily in the lung),
mice with metastases were randomized into four treatment
groups: (1) DMSO vehicle control; (2) 108600 (100 mg/kg q2D);
8

(3) PTX (10 mg/kg q4D); or (4) a combination of 108600 and
PTX. A total of 10–12 mice/treatment group were serially imaged
for metastases on days 18, 23, 28, and 32 by IVIS (Fig. 7A, B),
using the same acquisition settings for all treatment groups.
Acquisition timing after luciferin injection (15 min), exposure
time (5 min), lung gates (3.3 cm horizontal × 3.3 cm vertical),
were kept constant for all treatment groups and timepoints to
enable comparisons. At baseline, there was no signiﬁcant difference in metastatic disease burden among the four groups
(Fig. 7C). We also determined the ratio of luciferase signal from
lung metastases at different treatment timepoints (2nd, 3rd, 4th
IVIS) relative to the signal obtained at time of randomization (1st
IVIS) (Fig. 7D). While treatment with paclitaxel had little or no
effect on metastatic progression, treatment with 108600 alone had
an early suppressive effect on metastatic burden but the effect was
only partially sustained. However, combined treatment with
108600 and PTX signiﬁcantly and stably suppressed growth of
already established lung metastases. (Fig. 7D). These promising
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Fig. 7 108600 and paclitaxel synergize to inhibit established TNBC metastases. MDA-MB-231/LM2-4 mCherry cells were used to generate tumors in
the mammary fat pads of 7-week-old NSG mice. Surgery to remove the primary tumor was performed and all mice were imaged by IVIS for the presence of
metastases. A Schema of the experiment. Mice with metastases were randomized into four treatment groups (n = 10–12 per group) and metastatic disease
was monitored by serial IVIS imaging. B Serial IVIS imaging of mice in the four treatment groups. C Total luminescence in the region-of-interest (lung)
window for the four groups at time of treatment randomization (1st IVIS), showing no statistically signiﬁcant difference in lung metastases burden
(Dunnett’s test, two-sided). D The ratio of luminescence intensity compared to baseline luminescence (C) for each treatment group at serial timepoints
indicated in the schema. Ratios were calculated at each IVIS imaging. P values were calculated with Dunnett’s (two-sided) and Tukey’s tests (two-sided) in
comparison to the value for the DMSO-treated group. Each data point represents data obtained for an individual animal, with the top and bottom of the box
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results show that 108600 synergizes with chemotherapy to suppress TNBC metastatic growth, and support clinical translation of
108600/chemotherapy combination treatment for stage 4 TNBC.
Discussion
Resistance to chemotherapy remains a critical problem facing
patients diagnosed with TNBC, especially since suboptimal
response to chemotherapy is a strong predictor of long-term poor
prognosis. Multiple mechanisms have been proposed to contribute to chemotherapy resistance, among which is the presence
of a subpopulation of cells within the tumor that has stem-celllike properties with tumor initiation and self-renewal
capacity30,31. This population, which is characterized by
CD44high/CD24low expression32,33 as well as by high ALDH
activity34, is associated with chemotherapy resistance and worse
prognosis for multiple tumor types, and may contribute to tumor
progression and metastasis7,35–38. Therapeutically targeting this
population could enhance chemosensitivity and improve outcomes for patients. Here, we have identiﬁed a novel compound,
108600, identiﬁed in a screen for novel therapeutics that suppress
the BCSC-like population. 108600 synergizes with chemotherapy
to inhibit growth of aggressive TNBC that is resistant to standard
of care chemotherapy.
The efﬁcacy of 108600 lies in its potent simultaneous inhibition
of multiple signaling pathways that are active in CSCs and are
required for their maintenance and/or propagation. 108600’s
primary targets, CK2, DYRK, and TNIK kinases, collectively

activate signaling molecules such as STAT339,40, Wnt/βcatenin41–43, PI3K/AKT15,16, hedgehog44,45, and Notch146. These
proteins have been reported to be active in the CSC population,
are required for stem cell maintenance47 and contribute to drug
resistance and metastasis30,31. CK2, while ubiquitously expressed,
appears to be especially critical for growth and survival of cancer
cells48–50, with its activation being associated with aggressive
tumor behavior and higher levels correlating with poorer prognoses across multiple tumor types29,51–55. CK2 promotes the
activation of AKT15,16 and β-catenin42 by direct phosphorylation,
and NF-κβ signaling by phosphorylation and degradation of
IκBα56–59. Among the relevant substrates of CK2 that could
impact chemotherapy sensitivity are ABC proteins (P-gp/MDR
and MRP1) that are pumps responsible for efﬂux of chemotherapeutic agents60, and XRCC1/XRCC4 which regulate
DNA single and double-stranded break repair61. Inhibition of
CK2 kinase activity or its expression has been shown to inhibit
growth and induced apoptosis of multiple cancer cell types
in vitro62–65 and suppress the stem-like tumor initiating cells in
glioblastomas66,67.
In addition to CK2, other primary targets of 108600 play key
roles in the behavior of cancer stem cells. Class I DYRK kinases
have diverse functions in cell proliferation and differentiation by
regulating the degradation of key cell cycle regulators such as
CYCLIN D1 and p27KIP1 via phosphorylation17,68. These kinases
also modulate gene expression through direct effects on transcription factors and chromatin modiﬁcation. For example,
DYRK1A activates transcription factors critical for stem cell
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maintenance such as GLI1, a transcriptional effector of Hedgehog
signaling, and STAT369,70. TNIK, another 108600 target, activates
Wnt/β-catenin signaling as a component of the β-catenin/TCF4
transcriptional complex19,71, in addition to activating JNK and
NF-κB72. Importantly, this kinase also plays a key role in the
maintenance of tumor stem cells in vivo20.
Multiple mechanisms are responsible for the growth inhibition
and apoptosis induced by 108600 treatment. Our crystallographic
studies show that these effects are likely mediated, in part, by
direct inhibition of CK2-holoenzyme complex formation (Fig. 2).
At the cellular level, CK2 localizes to the mitotic apparatus and
regulates levels of core cell cycle proteins49,73. In agreement with
these studies, inhibition of tubulin polymerization, chromosome
mis-segregation and potent G2/M arrest observed with shortterm 108600 treatment lead to the induction apoptosis (Figs. 3, 4
and supplementary ﬁg. 12)74. 108600-treated cells are likely
sensitized to apoptotic triggers due to inhibition of multiple CK2/
DYRK/TNIK-dependent survival signaling pathways (AKT, NFkB, STAT), activation of caspases and direct suppression of antiapoptotic Bcl-2 family members, such as Bcl-xL and
survivin43,58,75. Finally, suppression of cells with ALDH-high,
CSC-like characteristics, as we observed in organoid cultures
derived from a chemotherapy-resistant TNBC PDX model treated
with 108600 (Fig. 6), might be critical for sensitizing malignant
cells to standard of care chemotherapy and eliminating a drugresistant population.
Small kinase inhibitors that individually target CK2, DYRK1,
or TNIK kinase are in various stages of preclinical development.
Treatment with NC-1, an oral inhibitor of TNIK, was reported to
suppress the ALDH-positive colon cancer CSC population, as
well as growth of tumor xenografts in preclinical models76. An
orally available CK2 inhibitor (CX-4945) has already been evaluated in Phase 1 clinical trials for solid tumors. While this agent
was found to be generally well tolerated, only partial responses
were observed77,78. These ﬁndings support the need for simultaneous inhibition of multiple signaling pathways to overcome
drug resistance in advanced cancers. Such ﬁndings are also consistent with our results showing that individual downregulation of
CK2α, DYRK1A, or TNIK had negligible effects in inhibiting
TNBC growth, whereas simultaneous downregulation of all three
kinases was required to phenocopy the effects of 108600 treatment (Fig. 1 and supplementary ﬁg. 4). Despite potent multikinase inhibition, 108600 treatment does not induce cell death of
normal cells (Fig. 1) and toxicities were not observed in our
in vivo studies using mouse models.
Our cell biological studies show that 108600 is extremely
potent in suppressing the growth of both CD44high/CD24low and
CD44low/CD24low TNBCs (Fig. 1). Moreover, 108600 induces
apoptosis of paclitaxel-resistant TNBCs in vitro (Fig. 5). We also
examined the efﬁcacy of 108600 using MDA-MB-231 xenografts
as well as two PDX models of TNBC that are resistant to paclitaxel. 108600 acts synergistically with paclitaxel in both PDX
models (Fig. 6), even when the tumors were non-responsive to
paclitaxel as a single agent. This observation is particularly signiﬁcant since chemotherapy resistance remains a critical problem
facing patients diagnosed with TNBC. Another major issue
encountered with TNBC patients is the highly metastatic nature
of this disease, which is the primary cause of patient mortality.
Our studies with LM2-4 cells, a highly metastatic variant of the
MDA-MB-231 cell line, show that 108600 is an effective suppressor of established metastases when administered in combination with paclitaxel (Fig. 7 and supplementary ﬁg. 17). This
property of 108600 may prove to be highly advantageous to
patients with advanced TNBC whose cancers are resistant to
chemotherapy.
10

In addition to direct effects on the tumor cell compartment, it
is possible that 108600 induces favorable changes in the immune
microenvironment of TNBC tumors that promote effective
antitumor immunity. Recently, it was reported that CK2 inhibition suppressed the differentiation of myeloid-derived suppressor
cells and tumor associated macrophages and synergized with
immune checkpoint inhibitors to suppress tumor growth79.
Therefore, 108600 could have effects on the immune microenvironment that also contribute to its potent antitumor effects,
raising the possibility that it might synergize with
immunotherapies.
In summary, we have identiﬁed a potent multi-kinase inhibitor
of CSCs that suppresses TNBC growth and overcomes resistance
to chemotherapy. 108600’s efﬁcacy against established metastatic
disease and its favorable toxicity proﬁle make it a promising
therapeutic for clinical translation. Effective inhibition of
chemotherapy-resistant TNBC, particularly the CSC-subpopulation, could lead to dramatic improvements in morbidity and
mortality associated with TNBC.
Methods
Cell lines. Established cell lines were purchased from ATCC. LM2-4/mCherry Luc
cells (LM2-4/mCherry) were a gift from Dr. Robert Kerbel (Sunnybrook) and were
maintained in Roswell Park Memorial Institute (RPMI) medium (ThermoFisher
Scientiﬁc) containing 5% FBS. MDA-MB-231, BT-20 and hMSC-hTERT cell lines
were maintained in DMEM supplemented with 10% FBS and 1× penicillinstreptomycin. Hs578T cells were cultured in DMEM supplemented with 10% FBS
and 10 µg/ml insulin (Sigma–Aldrich). HFLs were cultured in Ham’s F12 nutrient
mixture (ThermoFisher Scientiﬁc) supplanted with 10% FBS and 1× penicillinstreptomycin. All cell lines were maintained at 37 °C under humidiﬁed conditions
and 5% CO2.
PDX organoid cultures were maintained in F12/DMEM (GE healthcare,
Chicago, IL) containing 5% FBS (ThermoFisher Scientiﬁc), 10 mM HEPES
(ThermoFisher Scientiﬁc), 1 μg/ml bovine serum albumin (BSA) (Sigma–Aldrich,
St. Louis, MO), 1× insulin-transferrin-selenium (ThermoFisher Scientiﬁc), 0.5 µg/
ml hydrocortisone (Sigma–Aldrich), 2.5 µg/ml Fungizone (ThermoFisher
Scientiﬁc), 50 µg/ml Gentamicin (ThermoFisher Scientiﬁc), and 5 μM ROCK
inhibitor (Y27632) (Selleck Chemicals, Houston, TX).
Animals. Female nu/nu mice were purchased from Charles River Laboratories or
Taconic. Female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) and TNBC PDX
(TM00098)-bearing NSG mice were purchased from the Jackson Laboratory. Mice
used in all studies were 8–12 weeks of age at the start of the study. Animals were
housed in climate-controlled barrier conditions with automated light/dark cycles.
All animal experiments were performed under protocols approved by the Icahn
School of Medicine at Mount Sinai’s Institutional Animal Care and Use Committee
according to federal and institutional guidelines and regulations.
Patient samples. Samples from patients treated at the Mount Sinai Hospital were
collected for PDX generation and expansion. Written informed consent was
obtained for all subjects on Icahn School of Medicine at Mount Sinai (ISMMS)
Institutional Review Board (IRB)–approved protocol (HSM# 14-00330) prior to the
procedure at which the specimen was obtained. The studies were conducted in
accordance with the Belmont Report and U.S. Common Rule and approved by the
ISMMS IRB.
Reagents
Antibodies. Primary antibodies were purchased from Cell Signaling Technologies:
phospho-AKT1 (Ser129) (#13461), DYRK1A (#2771), DYRK1B (#2703), AKT1
(#2967), phospho-CYCLIN D1 (Thr286) (#3300), CYCLIN D1 (#2926), p27
(#3698), AXIN2 (#2151), TNIK (#32712), cleaved PARP (#9541 and #32563),
PARP (#9532 and #9542), cleaved Caspase 3 (#9661), CD44 (#3507), MDR-1
(#13342), c-Myc (#5605); Abcam: CK2α1 (ab76040), phospho-p27 (Ser10)
(ab62364), pericentrin (ab4448); Santa Cruz Biotechnology: GAPDH (sc-365062),
TNIK (sc-136103), CK2α2 (sc-9030), EGFR (sc-53274); BD Biosciences: PE CD44
(561858, 1:500), FITC CD24 (560992, 1:200); Invitrogen: ß-catenin (AH00462);
phospho-DYRK (PA5-64574). Secondary antibodies were purchased from Cell
Signaling Technologies (horse radish peroxidase [HRP] conjugated anti-rabbit IgG
[#7074]) or LICOR Biosciences (IRDye® 680 Goat anti-Mouse IgG (H + L) #92632220, IRDye® 800CW Goat anti-Rabbit IgG (H + L), #926-32211, IRDye® 680RD
Goat anti-Mouse IgG #926–68070, IRDye® 680RD Goat anti-Mouse IgG
#926–32210). Primary and secondary antibodies for western blot analysis were
used at 1:1,000 and 1:10,000 dilutions, respectively. Antibodies were used at a 1:200
dilution in immunoﬂuorescence staining.

NATURE COMMUNICATIONS | (2021)12:4671 | https://doi.org/10.1038/s41467-021-24878-z | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24878-z

Chemicals.
Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-ﬂuoromethylketone
(Z-VAD-FMK) was purchased from Cell Signaling Technology and
dissolved in dimethyl sulfoxide (DMSO) prior to use. Paclitaxel (Sigma–Aldrich)
was dissolved into 1:1 mixture of ethanol and Cremophore EL (GE healthcare) for
in vivo experiments. Four volumes of phosphate buffer saline without Ca2+ and
Mg2+ PBS(−) was added to the paclitaxel:cremophore mixture immediately before
every injection. 108600 was dissolved in DMSO immediately prior to each
injection.
Western blot analysis. Protein concentrations of whole-cell lysates were measured using the Lowry or bicinchoninic acid (BCA) assay. Lysates were resolved by
SDS-PAGE, transferred onto an Immobilon PVDF or nitrocellulose membrane and
incubated in primary antibody overnight at 4 °C. After secondary antibody incubation, the membranes were developed using ECL Western Blotting Substrate
(ThermoFisher Scientiﬁc or MiliporeSigma) or an Odyssey CLx imaging system
(LICOR Biosciences).
For in vivo tumor lysates, tumors were harvested 3 h after the ﬁnal treatment
and immediately snap frozen in liquid nitrogen. Frozen tumors were ground using
mortar and pestle and immediately lysed at 4 °C using radioimmunoprecipitation
assay (RIPA) buffer (Cell Signaling, Denver, MA). The lysates were centrifuged at
22,000 × g for 20 min at 4 °C, and the clariﬁed supernatant was collected for
subsequent western blot analysis.
Immunoprecipitation. Whole-cell lysates were harvested with RIPA buffer (Cell
signaling) and the concentrations measured using the BCA assay. One milligram of
whole-cell lysate was incubated with anti-TNIK antibody (Santa Cruz Biotechnology Inc., sc-136103) or its isotype control (Santa Cruz Biotechnology Inc.,
sc-3877) for 2 h at 4 °C. The lysates were then incubated with protein A/G-conjugated agarose (Santa Cruz Biotech., sc-2003) for 1 h at 4 °C, and centrifuged at
1000 × g for 5 min. to collect the precipitates. The precipitates were then washed
four times with RIPA buffer and denatured using 20 µL of 1× SDS sample buffer.
An identical concentration of whole-cell lysate was used as an input control.
Western blot analysis using anti-TNIK (Cell Signaling Technologies, #32712)
antibodies were performed to measure TNIK expression.
CK2α1 protein expression, puriﬁcation, and co-crystallization with 108600.
The CK2α1 catalytic domain was expressed and puriﬁed as described previously80.
Brieﬂy, a construct consisting of residues 3–339 encompassing the CK2α1 catalytic
domain was expressed in E. coli as His6-SUMO (small ubiquitin-like modiﬁer) Nterminally tagged fusion protein. The His6-SUMO tag was removed by cleavage
with Ulp1 protease after Ni-NTA afﬁnity chromatography and the protein was
further puriﬁed by Ni-NTA, heparin, and size-exclusion gel-ﬁltration column
chromatography (Supplementary Fig. 9). The crystals of CK2a1-108600 complex
were obtained by the vapor diffusion method at 20 °C and grew as thin plates. To
set up a crystallization drop, 1 μl of 10 mg/ml CK2α1 protein was mixed with 1 μl
of the reservoir solution containing 100 mM Tris-HCl pH 7.5, 200 mM ammonium
sulfate and 21% PEG5000 on a cover slide. 0.2 μl of 10 mM 108600 solution was
then added to the drop. 108600 was dissolved in 25% Cremophor EL, 24.5%
ethanol, 40% PEG 400, 5 mM Tris-HCL pH 8.0. The use of Cremophor EL-PEG
400-buffer mixture for 108600 solution preparation was critical for cocrystallization since 108600 dissolved in DMSO resulted in heavy precipitation in
the crystallization drop and the absence of crystal growth. The CK2α1-108600
complex crystals diffracted to high 1.80 Å resolution at 23ID synchrotron beamline
at the Argonne National Laboratory. The structure was solved by molecular
replacement with the CK2α1 catalytic domain (PDB ID: 3OWJ)81 as a search
model. The ﬁnal model was reﬁned to 1.80 Å resolution and Rwork/Rfree 17.5/22.1
(Supplementary Fig. 9E).
Tubulin polymerization assays. Microtubules were assembled in vitro from
puriﬁed Microtubule Associated Protein (MAP)-free tubulin (Cytoskeleton
Cat#TL238c) at 2 mg/ml in manufacturer-supplied PEM buffer supplemented with
1 mm GTP at 35 °C, and the turbidity of the solutions was monitored at 340 nm.
DMSO or 108600 at varying concentrations was preincubated with recombinant
puriﬁed CK2α1 (30 ng/ml) for 30 min and an equal concentration of recombinant
CK2β was then added to the mixture. This mixture was then added to the MAPfree tubulin to initiate CK2-holoenzyme-dependent polymerization. The rate of
tubulin polymerization was measured using densitometry at 2-minute intervals.
siRNA transfection. siRNA transfections were performed using Oligofectamine
(ThermoFisher Scientiﬁc, Inc.). siGENOME SMART pools (Horizon Discovery)
for CSNK2A1 (M-003475-03-0005), DYRK1A (M-00485-01-005), and TNIK (M004542-03-0005), and non-targeting control siRNAs (D-001210-05-50) were
transfected according to the manufacturer’s protocol. Brieﬂy, the culture medium
was changed to Opti-MEM (ThermoFisher Scientiﬁc, Inc.) prior to transfection,
and the mixture of Oligofectamine and 30 nM of each siRNA pool were added to
the cells. Media containing 3× serum was added to the cells after a 5 h incubation at
37 °C. The cells were harvested 96 h post-transfection.
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Flow cytometry
Cell cycle analysis. Organoids were washed and harvested with PBS (−) and TrypLE (ThermoFisher Scientiﬁc), and then ﬁxed with ice-cold 95% ethanol for a
minimum of 24 h. The cells were then washed twice with PBS(−) and stained with
PI/RNase staining buffer (Becton Dickinson, Franklin Lakes, NJ) for 15 min. at
room temperature. Flow cytometric analysis was performed using an LSRII Fortessa (Becton Dickinson) and the data analyzed using FCS Express 6.0 (De Novo
Software, Glendale, CA) or FlowJo™ v9 (BD Biosciences).
Aldeﬂuor assay. ALDEFLOUR™ Kit (Stemcell Technologies, Vancouver, Canada)
was used according to manufacturer’s instructions. Organoids were washed twice
with PBS(−) and then incubated with digestion buffer, (1 mg/ml Collagenase IV,
100 units/ml hyalronidase, and 100 µg/ml DNase I in PBS(−)), with shaking at 200
rpm. for 15 min at 37 °C. Organoids were incubated with Aldeﬂour solution at 37 °
C for 60 min. DEAB (Stemcell Technologies) treatment was used as a negative
control to set the gating for the ALDHhigh fraction.
Isolation of BCSC populations. Single-cell suspensions were prepared in phenol redfree RPMI supplemented with 2% heat-inactivated FBS. Deﬁned numbers of cells
were stained on ice for 1 h, washed, and then subjected to ﬂow cytometric analysis.
Antibodies used were as follows: anti-CD44 PE (BD Biosciences 561858) and antiCD24 FITC (BD Biosciences 560992). DAPI was used at a concentration of 10 ng/
ml as a measurement of viability. Flow cytometric sorting was performed by the
Flow Cytometry Shared Resource Facility at the Icahn School of Medicine at
Mount Sinai using a FACSAria II (BD Biosciences). Data were acquired using
FACSDivaTM v8.0 and analyzed using FCS Express 6.0 (De Novo Software,
Glendale, CA) or FlowJo™ v9 (BD Biosciences).
Immunoﬂuorescence and confocal microscopy. Exponentially growing cells were
seeded at a density of at 0.1 × 105 cells/ml in 100 mm dishes containing sterilized
glass microscope coverslips and allowed to transﬁx overnight. The next day, cells
were treated with DMSO or 108600 for 12 h. Coverslips were gently washed with
PBS, ﬁxed with 4% paraformaldehyde for 15 min and washed three times with PBS
for 5 mins. Cells were then permeabilized using 0.1% Triton X-100 in PBS for 15
min at room temperature. After another PBS wash, coverslips were incubated in
blocking buffer (1% BSA in PBST) for 1 h at 37 °C. The cells were incubated with
anti-α-tubulin-FITC (Sigma–Aldrich # F2168) and anti-pericentrin (Abcam,
ab4448) antibodies diluted 1:200 in blocking buffer for 1 h at 37 °C. The coverslips
were again washed three times with PBS and stained with Texas red goat antirabbit secondary antibody (BD Biosciences, T2767). Coverslips were washed again
with PBS and incubated in 1 μg/mL DAPI solution (Southernbiotech 0100-20) for
5 min before being washed two times with PBS. Finally, coverslips were mounted
onto glass slides using ProLong® Gold Antifade Reagent (ThermoFisher Scientiﬁc,
P36930) and dried overnight in the dark before being imaged.
In vitro kinase assays. In vitro kinase assays were performed as previously
described by us82. Brieﬂy, 10 ng of recombinant protein (ThermoFisher Scientiﬁc)
was diluted in kinase buffer (20 mM HEPES [pH 7.5], 10 mM MgCl2, 1 mM EGTA,
0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO and
incubated with the indicated concentrations of 108600 at room temperature for 30
min. Kinase reactions were initiated by the addition of 1 μg substrate and mixture
of 10 µM ATP (Sigma–Aldrich) and 100 µCi 33P-γ-ATP (PerkinElmer). The
reactions were incubated for 2 h at 25 °C and subsequently spotted onto P81 ion
exchange ﬁlter paper. The ﬁlters were then thoroughly washed in 0.75% phosphoric
acid to remove unbound phosphate and the level of substrate radioactivity quantitated using a scintillation counter. Values were plotted as a function of log drug
concentration and IC50 values determined by plotting sigmoidal non-linear
regression curves with a variable slope. Peptide substrates used were as follows:
CK2α and CK2α2: RRRDDDSDDD; TNIK: RLGDKYKTLRQIRQ; DYRK1:
RRRFRPASPLRGPPK.
Viability assays and GI50 value determination. 2.5 × 103 cells were seeded into
each well of a black, clear-bottom 96-well plate and treated with 108600 24 h postplating. Fluorescence was measured by excitation at 579 nm and an emission at
594 nm after a 96 h incubation using CellTiter-Blue reagent (Promega). GI50 values
were calculated by normalizing ﬂuorescence values to those of DMSO-treated
controls after background subtraction.
In vivo tumor efﬁcacy studies. For MDA-MB-231 xenografts, 1 × 107 cells in 0.2
ml of sterile PBS were subcutaneously injected into the mammary fat pads of Ncrnu/nu mice. PDX tumor grafts were propagated as follows: 4–5 mm frozen tumor
fragments were subcutaneously transplanted into the right ﬂank of NSG mice.
Approximately 1 month after primary transplantation, the growing tumors were
harvested, cut into 5 mm tumor fragments, and retransplanted into cohorts of NSG
mice. When tumor grafts reached ~50–100 mm3 in size, treatment was initiated
with intraperitoneal injections of paclitaxel or 108600 injected every 4 or 2 days,
respectively. DMSO was used as control. Body weights and tumor volumes were
measured by calipers every 2 or 3 days and volume estimated using the formula: ½
(width2 × length). Where indicated, preengrafted, PDX-bearing NSG mice
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(TM00098) purchased from the Jackson Laboratory were used for efﬁcacy studies
that followed the above dosing and monitoring protocols.

2.

In vivo imaging (IVIS). 5 × 105 LM2-4/mCherry cells were injected into the right
inguinal mammary fat pad of NSG mice. Eleven days after injection, the primary
tumor and the mammary fat pad were surgically removed. NSG mice were anesthetized using inﬂowing isoﬂurane (2–2.5%) in 2–2.5 L/min oxygen, and placed into
the imaging chamber, and background luminescence was acquired. 10 µL/g mouse
body weight of luciferin (PerkinElmer Inc., Waltham, MA) was injected intraperitoneally. One minute after the injection of luciferin, luminescence was acquired to
check for presence of metastasis or residual tumor. To block luminescence from any
residual primary tumor, the area around the inguinal mammary fat pad was covered
with black aluminum foil and clay. Luciferin signals were acquired 5, 15, and 25
min. after luciferin injection. The luminescence intensity at 15 min. was used for the
quantitative analysis. To analyze the lung metastasis, a 3.3 × 3.3 cm window was set
as region of interest (ROI) prior to measuring radiance.
Mice with metastases were selected based on the luminescence signal at the ﬁrst
IVIS imaging following primary tumor removal, and each mouse was randomly
assigned to DMSO, 108600, paclitaxel or 108600/paclitaxel combination treatment
groups. DMSO and 108600 were intraperitoneally injected every 2 days and
paclitaxel was injected every 4 days for 2 weeks. The luminescence intensity at the
ﬁrst IVIS imaging was used as a baseline intensity for each mouse, and the ratio of
luminescence between each IVIS imaging and baseline was used for comparison.
Living Image (version 4.7.2, PerkinElmer Inc.) was used for acquisition and
analysis of luminescence intensity.

3.

Preparation of organoid cultures. Frozen small tumor fragments in Cellbanker 1
(Nippon Zenyaku Kogyo) at −80 °C were used for making organoids. After
thawing, the fragments were cut, minced and incubated in digestion buffer at 37 °C
with shaking. After digestion, the cell suspension was ﬁltered (100 μm) and centrifuged. Pellets were collected and resuspended in human breast epithelial cell
(HBEC) medium (5% FBS, 10 mM HEPES, BSA, 0.5 µg/ml hydrocortisone, 50 µg/
ml gentamycin, 2.5 µg/ml Fungizone, 1× insulin-transferrin-selenium, and 5 μM
ROCK inhibitor (Y27632) (Selleck Chemicals) in DMEM/F1283. Ficoll density
gradient centrifugation was performed and the live cell fraction was collected. After
washing with PBS, cells were seeded on nonadherent 24-well plate. Nonviable cells
were removed by density gradient centrifugation 3 days post-plating.
Colony-formation assays. Sorted cells were plated into six-well plates at 750 cells/
well and allowed to adhere overnight. 108600 was then added at varying concentrations for a 72 h period. Drug-containing medium was replaced with fresh
medium and the cells were incubated for an additional 8–10 days with media
changes made every 3 days. Cells were ﬁxed in methanol (−20 °C) and stained with
5% crystal violet. Colonies were counted using ImageJ v1.5.
Mammosphere-formation assays. TNBC cell lines, sorted BCSCs from cell lines
and patient-derived human breast cancer stem cells (XLC479, Creative Bioarray)
were cultured in suspension in serum free DMEM/F12 1:1 supplemented with EGF
(20 ng/ml, BD Biosciences), B27 (1:50, Invitrogen), 0.4% bovine serum albumin
(Sigma–Aldrich), and 4 μg/ml insulin (Sigma–Aldrich) on Costar ultralow
attachment multi-well plates (Corning Cat#3471). Cells were grown in DMSO or
108600 (200 nM) for 72 h. Drug-containing medium was replaced with fresh
medium and the cells were further incubated for 1–2 weeks to induce mammosphere formation.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

4.
5.

6.

7.

8.

9.

10.

11.
12.
13.
14.
15.
16.

17.

18.

19.
20.
21.
22.

23.

24.

Data availability

25.

Atomic coordinates and structure factors have been deposited in the Protein Data Bank
(PDB) under accession code 7L1X. Source data are provided with this paper.

26.

Materials availability
Request for materials generated in this study should be directed to the corresponding
authors and will be made available upon execution of a Material Transfer Agreement.

27.
28.
29.

Received: 17 July 2020; Accepted: 8 July 2021;

30.

31.

References
1.

12

Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into molecular
classiﬁcations of triple-negative breast cancer: improving patient selection for
treatment. Cancer Discov. 9, 176–198 (2019).

32.

Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in
patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275–1281
(2008).
von Minckwitz, G. et al. Deﬁnition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various intrinsic
breast cancer subtypes. J. Clin. Oncol. 30, 1796–1804 (2012).
Bao, B. & Prasad, A. S. Targeting CSC in a most aggressive subtype of breast
cancer TNBC. Adv. Exp. Med. Biol. 1152, 311–334 (2019).
Lee, K. L., Kuo, Y. C., Ho, Y. S. & Huang, Y. H. Triple-negative breast cancer:
current understanding and future therapeutic breakthrough targeting cancer
stemness. Cancers (Basel) 11, 1334 (2019).
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M.
F. Prospective identiﬁcation of tumorigenic breast cancer cells. Proc. Natl
Acad. Sci. USA 100, 3983–3988 (2003).
Ginestier, C. et al. ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1,
555–567 (2007).
Montgomery, N. et al. CD44 enhances invasion of basal-like breast cancer cells
by upregulating serine protease and collagen-degrading enzymatic expression
and activity. Breast Cancer Res. 14, R84 (2012).
So, J. Y. et al. Targeting CD44-STAT3 signaling by Gemini vitamin D analog
leads to inhibition of invasion in basal-like breast cancer. PLoS ONE 8, e54020
(2013).
Ma, F. et al. Aldehyde dehydrogenase 1 (ALDH1) expression is an
independent prognostic factor in triple negative breast cancer (TNBC).
Medicine 96, e6561 (2017).
Zhong, Y. et al. ALDH1 is a better clinical indicator for relapse of invasive ductal
breast cancer than the CD44+/CD24- phenotype. Med. Oncol. 31, 864 (2014).
Ashworth, A. & Bernards, R. Using functional genetics to understand breast
cancer biology. Cold Spring Harb. Perspect. Biol. 2, a003327 (2010).
Iorns, E., Lord, C. J., Turner, N. & Ashworth, A. Utilizing RNA interference to
enhance cancer drug discovery. Nat. Rev. Drug Discov. 6, 556–568 (2007).
Knight, Z. A., Lin, H. & Shokat, K. M. Targeting the cancer kinome through
polypharmacology. Nat. Rev. Cancer 10, 130–137 (2010).
Di Maira, G. et al. Protein kinase CK2 phosphorylates and upregulates Akt/
PKB. Cell Death Differ. 12, 668–677 (2005).
Di Maira, G., Brustolon, F., Pinna, L. A. & Ruzzene, M. Dephosphorylation
and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK
293T cells. Cell Mol. Life Sci. 66, 3363–3373 (2009).
Soppa, U. et al. The Down syndrome-related protein kinase DYRK1A
phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and
neuronal differentiation. Cell Cycle 13, 2084–2100 (2014).
Jho, E. H. et al. Wnt/beta-catenin/Tcf signaling induces the transcription of
Axin2, a negative regulator of the signaling pathway. Mol. Cell Biol. 22,
1172–1183 (2002).
Mahmoudi, T. et al. The kinase TNIK is an essential activator of Wnt target
genes. EMBO J. 28, 3329–3340 (2009).
Masuda, M. et al. TNIK inhibition abrogates colorectal cancer stemness. Nat.
Commun. 7, 12586 (2016).
Ferguson, A. D. et al. Structural basis of CX-4945 binding to human protein
kinase CK2. FEBS Lett. 585, 104–110 (2011).
Nieﬁnd, K., Putter, M., Guerra, B., Issinger, O. G. & Schomburg, D. GTP plus
water mimic ATP in the active site of protein kinase CK2. Nat. Struct. Biol. 6,
1100–1103 (1999).
Nieﬁnd, K., Guerra, B., Ermakowa, I. & Issinger, O. G. Crystal structure of
human protein kinase CK2: insights into basic properties of the CK2
holoenzyme. EMBO J. 20, 5320–5331 (2001).
Lim, A. C., Hou, Z., Goh, C. P. & Qi, R. Z. Protein kinase CK2 is an inhibitor
of the neuronal Cdk5 kinase. J. Biol. Chem. 279, 46668–46673 (2004).
Bettencourt-Dias, M. et al. Genome-wide survey of protein kinases required
for cell cycle progression. Nature 432, 980–987 (2004).
Faust, M., Schuster, N. & Montenarh, M. Speciﬁc binding of protein kinase
CK2 catalytic subunits to tubulin. FEBS Lett. 462, 51–56 (1999).
Lim, A. C., Tiu, S. Y., Li, Q. & Qi, R. Z. Direct regulation of microtubule
dynamics by protein kinase CK2. J. Biol. Chem. 279, 4433–4439 (2004).
Al-Hajj, M. Cancer stem cells and oncology therapeutics. Curr. Opin. Oncol.
19, 61–64 (2007).
Liu, R. et al. The prognostic role of a gene signature from tumorigenic breastcancer cells. N. Engl. J. Med. 356, 217–226 (2007).
Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours:
accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755–768
(2008).
Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the
mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611–629
(2017).
Fillmore, C. M. & Kuperwasser, C. Human breast cancer cell lines contain
stem-like cells that self-renew, give rise to phenotypically diverse progeny and
survive chemotherapy. Breast Cancer Res. 10, R25 (2008).

NATURE COMMUNICATIONS | (2021)12:4671 | https://doi.org/10.1038/s41467-021-24878-z | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24878-z

33. Klonisch, T. et al. Cancer stem cell markers in common cancers—therapeutic
implications. Trends Mol. Med. 14, 450–460 (2008).
34. Charafe-Jauffret, E. et al. Breast cancer cell lines contain functional cancer
stem cells with metastatic capacity and a distinct molecular signature. Cancer
Res. 69, 1302–1313 (2009).
35. Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in
poorly differentiated aggressive human tumors. Nat. Genet. 40, 499–507
(2008).
36. Silva, I. A. et al. Aldehyde dehydrogenase in combination with CD133 deﬁnes
angiogenic ovarian cancer stem cells that portend poor patient survival.
Cancer Res. 71, 3991–4001 (2011).
37. Liebscher, C. A. et al. Aldehyde dehydrogenase 1/epidermal growth factor
receptor coexpression is characteristic of a highly aggressive, poor-prognosis
subgroup of high-grade serous ovarian carcinoma. Hum. Pathol. 44,
1465–1471 (2013).
38. Kida, K. et al. Effect of ALDH1 on prognosis and chemoresistance by breast
cancer subtype. Breast Cancer Res. Treat. 156, 261–269 (2016).
39. Fernandez-Martinez, P., Zahonero, C. & Sanchez-Gomez, P. DYRK1A: the
double-edged kinase as a protagonist in cell growth and tumorigenesis. Mol.
Cell Oncol. 2, e970048 (2015).
40. Gao, J. et al. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in
non-small cell lung cancer cells. Cancer Biol. Ther. 8, 1671–1679 (2009).
41. Wang, S. & Jones, K. A. CK2 controls the recruitment of Wnt regulators to
target genes in vivo. Curr. Biol. 16, 2239–2244 (2006).
42. Song, D. H. et al. CK2 phosphorylation of the armadillo repeat region of betacatenin potentiates Wnt signaling. J. Biol. Chem. 278, 24018–24025 (2003).
43. Tapia, J. C., Torres, V. A., Rodriguez, D. A., Leyton, L. & Quest, A. F. Casein
kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell
factor/lymphoid enhancer binding factor-dependent transcription. Proc. Natl
Acad. Sci. USA 103, 15079–15084 (2006).
44. Zhang, S. et al. CK2alpha, over-expressed in human malignant pleural
mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma
cells. J. Exp. Clin. Cancer Res. 33, 93 (2014).
45. Zhang, S. et al. Inhibition of CK2alpha down-regulates Hedgehog/Gli
signaling leading to a reduction of a stem-like side population in human lung
cancer cells. PLoS ONE 7, e38996 (2012).
46. Zhang, S. et al. Inhibition of CK2alpha down-regulates Notch1 signalling in
lung cancer cells. J. Cell Mol. Med. 17, 854–862 (2013).
47. Nalla, L. V., Kalia, K. & Khairnar, A. Self-renewal signaling pathways in breast
cancer stem cells. Int. J. Biochem. Cell Biol. 107, 140–153 (2019).
48. Bian, Y. et al. Global screening of CK2 kinase substrates by an integrated
phosphoproteomics workﬂow. Sci. Rep. 3, 3460 (2013).
49. Rusin, S. F., Adamo, M. E. & Kettenbach, A. N. Identiﬁcation of candidate
casein kinase 2 substrates in mitosis by quantitative phosphoproteomics.
Front. Cell Dev. Biol. 5, 97 (2017).
50. Gyenis, L. & Litchﬁeld, D. W. The emerging CK2 interactome: insights into
the regulation and functions of CK2. Mol. Cell Biochem. 316, 5–14 (2008).
51. Landesman-Bollag, E. et al. Protein kinase CK2: signaling and tumorigenesis
in the mammary gland. Mol. Cell Biochem. 227, 153–165 (2001).
52. Giusiano, S. et al. Protein kinase CK2alpha subunit over-expression correlates
with metastatic risk in breast carcinomas: quantitative immunohistochemistry
in tissue microarrays. Eur. J. Cancer 47, 792–801 (2011).
53. Laramas, M. et al. Nuclear localization of protein kinase CK2 catalytic subunit
(CK2alpha) is associated with poor prognostic factors in human prostate
cancer. Eur. J. Cancer 43, 928–934 (2007).
54. Gapany, M. et al. Association of elevated protein kinase CK2 activity with
aggressive behavior of squamous cell carcinoma of the head and neck. Mol.
Med. 1, 659–666 (1995).
55. Landesman-Bollag, E. et al. Protein kinase CK2 in mammary gland
tumorigenesis. Oncogene 20, 3247–3257 (2001).
56. Dominguez, I., Sonenshein, G. E. & Seldin, D. C. Protein kinase CK2 in health
and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking
development and cancer. Cell Mol. Life Sci. 66, 1850–1857 (2009).
57. McElhinny, J. A., Trushin, S. A., Bren, G. D., Chester, N. & Paya, C. V. Casein
kinase II phosphorylates I kappa B alpha at S-283, S-289, S-293, and T-291
and is required for its degradation. Mol. Cell Biol. 16, 899–906 (1996).
58. Romieu-Mourez, R., Landesman-Bollag, E., Seldin, D. C. & Sonenshein, G. E.
Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB,
transformed phenotype, and survival of breast cancer cells. Cancer Res. 62,
6770–6778 (2002).
59. Wang, D., Westerheide, S. D., Hanson, J. L. & Baldwin, A. S. Jr. Tumor
necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is
controlled by casein kinase II. J. Biol. Chem. 275, 32592–32597 (2000).
60. Stolarczyk, E. I. et al. Casein kinase 2alpha regulates multidrug resistanceassociated protein 1 function via phosphorylation of Thr249. Mol. Pharmacol.
82, 488–499 (2012).
61. Siddiqui-Jain, A. et al. CK2 inhibitor CX-4945 suppresses DNA repair
response triggered by DNA-targeted anticancer drugs and augments efﬁcacy:

62.
63.
64.

65.

66.

67.

68.

69.

70.
71.

72.

73.

74.

75.

76.

77.

78.

79.

80.

81.

82.

83.

mechanistic rationale for drug combination therapy. Mol. Cancer Ther. 11,
994–1005 (2012).
Takahashi, K. et al. Inhibition of casein kinase 2 prevents growth of human
osteosarcoma. Oncol. Rep. 37, 1141–1147 (2017).
Hamacher, R. et al. Casein kinase II inhibition induces apoptosis in pancreatic
cancer cells. Oncol. Rep. 18, 695–701 (2007).
So, K. S. et al. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor,
promotes apoptosis in chemorefractory non-small cell lung cancer cells.
Anticancer Res. 35, 1537–1542 (2015).
Slaton, J. W., Unger, G. M., Sloper, D. T., Davis, A. T. & Ahmed, K. Induction
of apoptosis by antisense CK2 in human prostate cancer xenograft model.
Mol. Cancer Res. 2, 712–721 (2004).
Rowse, A. L. et al. Protein kinase CK2 is important for the function
of glioblastoma brain tumor initiating cells. J. Neurooncol 132, 219–229
(2017).
Nitta, R. T. et al. Casein kinase 2alpha regulates glioblastoma brain tumorinitiating cell growth through the beta-catenin pathway. Oncogene 34,
3688–3699 (2015).
Chen, J. Y., Lin, J. R., Tsai, F. C. & Meyer, T. Dosage of Dyrk1a shifts cells
within a p21-cyclin D1 signaling map to control the decision to enter the cell
cycle. Mol. Cell 52, 87–100 (2013).
Kurabayashi, N., Nguyen, M. D. & Sanada, K. DYRK1A overexpression
enhances STAT activity and astrogliogenesis in a Down syndrome mouse
model. EMBO Rep. 16, 1548–1562 (2015).
Mao, J. et al. Regulation of Gli1 transcriptional activity in the nucleus by
Dyrk1. J. Biol. Chem. 277, 35156–35161 (2002).
Masuda, M., Sawa, M. & Yamada, T. Therapeutic targets in the Wnt signaling
pathway: feasibility of targeting TNIK in colorectal cancer. Pharmacol. Ther.
156, 1–9 (2015).
Shkoda, A. et al. The germinal center kinase TNIK is required for canonical
NF-kappaB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and
the CD40 receptor. PLoS Biol. 10, e1001376 (2012).
Bosc, D. G., Luscher, B. & Litchﬁeld, D. W. Expression and regulation of
protein kinase CK2 during the cell cycle. Mol. Cell Biochem. 191, 213–222
(1999).
Lin, F., Cao, S. B., Ma, X. S. & Sun, H. X. Inhibition of casein kinase 2 blocks
G2/M transition in early embryo mitosis but not in oocyte meiosis in mouse. J.
Reprod. Dev. 63, 319–324 (2017).
Ponce, D. P. et al. CK2 functionally interacts with AKT/PKB to promote the
beta-catenin-dependent expression of survivin and enhance cell survival. Mol.
Cell Biochem. 356, 127–132 (2011).
Uno, Y. et al. A novel TNIK inhibitor potently downregulates cancer stem cell
population through attenuation of Wnt signaling [abstract]. in AACR-NCIEORTC International Conference (2018).
Pierre, F. et al. Pre-clinical characterization of CX-4945, a potent and selective
small molecule inhibitor of CK2 for the treatment of cancer. Mol. Cell
Biochem. 356, 37–43 (2011).
Siddiqui-Jain, A. et al. CX-4945, an orally bioavailable selective inhibitor of
protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits
antitumor efﬁcacy. Cancer Res. 70, 10288–10298 (2010).
Hashimoto, A. et al. Inhibition of casein kinase 2 disrupts differentiation of
myeloid cells in cancer and enhances the efﬁcacy of immunotherapy in mice.
Cancer Res. 78, 5644–5655 (2018).
Padgaonkar, A. et al. Targeting protein kinase CK2 and CDK4/6 pathways
with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and
growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.
Oncotarget 9, 37753–37765 (2018).
Prudent, R. et al. Antitumor activity of pyridocarbazole and
benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res. 70,
9865–9874 (2010).
Divakar, S. K. et al. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR
pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
Leukemia 30, 86–93 (2016).
DeRose, Y. S. et al. Patient-derived models of human breast cancer:
protocols for in vitro and in vivo applications in tumor biology and
translational medicine. Chapter 14, Unit 14.23, Curr. Protoc. Pharmacol.
(2013).

Acknowledgements
This work was supported by grants from the Breast Cancer Alliance and the Department
of Defense (BC161776, BC161776P1) to E.P.R. and H.Y.I., the Breast Cancer Research
Foundation (BCRF-20-130) to E.R.P. and H.Y.I., and the National Institutes of Health
(R35-GM131780) to A.K.A. Use of the ﬂow cytometry shared resource facility was
supported by a NIH Cancer Center Support Grant (P30CA196521) to the Tisch Cancer
Institute.

NATURE COMMUNICATIONS | (2021)12:4671 | https://doi.org/10.1038/s41467-021-24878-z | www.nature.com/naturecommunications

13

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24878-z

Author contributions

Reprints and permission information is available at http://www.nature.com/reprints

K.S., A.P., S.B., S.C., O.R., D.S., J.D., A.B. and E.P. conducted experiments; A.A., M.R.,
H.I. and E.R. designed experiments and K.S., A.P., S.B., O.R., A.A., H.I. and E.R. wrote
the manuscript.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41467-021-24878-z.
Correspondence and requests for materials should be addressed to H.Y.I. or E.P.R.
Peer review information Nature Communications thanks Khalil Ahmed, Saraswati
Sukumar and the other anonymous reviewer(s) for their contribution to the peer review
of this work.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021

14

NATURE COMMUNICATIONS | (2021)12:4671 | https://doi.org/10.1038/s41467-021-24878-z | www.nature.com/naturecommunications

